MBX Biosciences Inc
Pharmaceuticals
MBX Biosciences Inc (MBX) Stock News
The latest MBX headlines and market coverage — 4 recent stories, updated throughout the day.
- GlobeNewswire Inc.·Neutral
Multibeam sichert sich ersten Auftrag aus Taiwan für die neu eingeführte MBX-Plattform – das Multisäulen-Elektronenstrahllithografiesystem der zweiten Generation des Unternehmens
Multibeam Corp. announced that National Tsing Hua University (NTHU) in Taiwan has ordered its MBX multi-column electron beam lithography system for advanced chip manufacturing research. The system will be used for developing new manufacturing processes and accelerating next-generation chip integration. Delivery is scheduled for 2027, marking Multibeam's first system installation in Taiwan.
- GlobeNewswire Inc.·Neutral
Multibeam décroche sa première commande à Taïwan pour sa nouvelle plateforme MBX – le système de lithographie par faisceau d’électrons multi-colonnes de deuxième génération de l’entreprise
Multibeam Corp. announced its first order in Taiwan from National Tsing Hua University (NTHU) for its MBX multi-column electron beam lithography system. The system will support advanced chip integration research and joint development projects with major Taiwanese chipmakers, with delivery expected in 2027. This marks Multibeam's entry into Taiwan, the world's most critical IC manufacturing region.
- GlobeNewswire Inc.·
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
MBX Biosciences announced positive one-year data from its open-label extension study of canvuparatide, a once-weekly PTH replacement therapy for chronic hypoparathyroidism. The drug maintained a 57% responder rate at one year with a 90% retention rate, demonstrated sustained benefits in calcium homeostasis, kidney function, and bone metabolism, and showed no new safety signals. The company remains on track to initiate Phase 3 pivotal trials in Q3 2026.
- GlobeNewswire Inc.·
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
MBX Biosciences announced preliminary Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug showing 7% mean weight loss at 8 weeks with good tolerability and potential for once-monthly dosing. The company also nominated MBX 5765, a novel four-agonist candidate for obesity, and achieved proof of concept for imapextide in post-bariatric hypoglycemia, though will not pursue further Phase 2b development of the latter to prioritize resources.